淋巴瘤 在华治疗
对于复发或难治性大B细胞淋巴瘤，中国有四款获批的CD19 CAR-T产品：axi-cel、relma-cel、瑞基奥仑赛和纳基奥仑赛。其中仅axi-cel同时获FDA批准。卡瑞利珠单抗在中国获批用于三线经典型霍奇金淋巴瘤。患者可通过医院血液科或临床试验获取治疗。
已核验最后核验
可用疗法
| 可用疗法 | 在华状态 | 在美状态 | 信息来源 |
|---|---|---|---|
| Axicabtagene ciloleucel (Yikaida / Yescarta), CD19 CAR-T | 在中国已获批 | 在中国已获批 | National Healthcare Security AdministrationElevar Therapeutics / GlobeNewswire |
| Relmacabtagene autoleucel (Carteyva), CD19 CAR-T | 在中国已获批 | 未获批 | PubMed CentralElevar Therapeutics / GlobeNewswire |
| Ranicabtagene autoleucel (HICARA), CD19 CAR-T | 在中国已获批 | 未获批 | JW TherapeuticsElevar Therapeutics / GlobeNewswire |
| Inaticabtagene autoleucel, CD19 CAR-T | 在中国已获批 | 未获批 | Elevar Therapeutics / GlobeNewswire |
| Camrelizumab (PD-1) for relapsed/refractory classic Hodgkin lymphoma, third line | 在中国已获批 | 未获批 | Shanghai Hengrun Dasheng (Harin Bio) |
有公开项目的医院
以下为有来源的公开信息，不构成推荐。
Shanghai上海交通大学医学院附属瑞金医院Ruijin Hospital, Shanghai Jiao Tong University School of MedicineInternational deptVerified
Shanghai复旦大学附属肿瘤医院Fudan University Shanghai Cancer CenterInternational deptReported
Beijing北京大学肿瘤医院Peking University Cancer Hospital (Beijing Cancer Hospital)No public intl deptVerified
Guangzhou中山大学肿瘤防治中心Sun Yat-sen University Cancer CenterInternational deptVerified
Hainan / Boao Lecheng上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）Ruijin Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Boao Research Hospital)International deptReported
临床试验
585项研究正在中国招募（ClinicalTrials.gov，截至 2026-10-26）. 查看列表
我们只提供试验链接；是否入组由试验团队决定。据 AFP 报道，自 2026 年 5 月起中国禁止向患者收取临床研究费用。
常见问题
中国有多少款治疗淋巴瘤的CAR-T产品？
2026年6月国家医保局文件列出四款用于复发或难治性大B细胞淋巴瘤的已上市CAR-T产品：阿基仑赛、瑞基奥仑赛、瑞基奥仑赛和纳基奥仑赛。瑞基奥仑赛还适用于滤泡性淋巴瘤。
[1] National Healthcare …[2] JW Therapeutics淋巴瘤CAR-T是否纳入中国国家医保？
截至2026年6月尚未纳入：国家医保局文件显示，这四款产品均未进入国家基本医疗保险药品目录。外国患者通常需自费。
[1] National Healthcare …信息来源
- 2026 National Reimbursement Drug List application: ranicabtagene autoleucel (public version)
“In r/r large B-cell lymphoma, four CAR-T products are marketed in China (axicabtagene, relmacabtagene, ranicabtagene, inaticabtagene), none yet in the national basic medical insurance drug list.”
- A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product
“Lists Yikaida (axicabtagene ciloleucel) at about 1.166 million yuan per infusion and inaticabtagene at about 0.999 million yuan.”
- NMPA acceptance of sBLA for Carteyva as second-line treatment in r/r LBCL
“Carteyva has been approved by NMPA for three indications.”
- Harin Bio's CD19 CAR-T HICARA (Ranicabtagene Autoleucel Injection) Approved for Marketing
“On July 30, 2025, the National Medical Products Administration formally approved the New Drug Application for Ranicabtagene Autoleucel Injection (HICARA).”
- Elevar Therapeutics Receives FDA Complete Response Letter for rivoceranib plus camrelizumab in HCC
“Camrelizumab is currently approved for eight indications in China, including relapsed/refractory classic Hodgkin's lymphoma (third-line) and esophageal squamous cell carcinoma.”
- 16 CAR-T Therapies and Counting
“Seven therapies have been approved by the U.S. FDA.”
本站仅提供信息，不构成医疗建议、诊断或治疗推荐。请咨询你的医生。紧急情况请立即拨打当地急救电话。